HopeStage
Back to all studies
CompletedNCT06567587

Dexmedetomidine for agitation in people with psychosis and COPD

About this titleRead the official source — NCT06567587
Observational studyAges 18–60EgyptSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 60 years.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: June 10, 2024
Recruitment status
Completed
Enrollment listed in the registry
70
Sponsor
Tanta University
Sponsor type
University
Study type
Observational
Intervention type
Device, Drug
Locations
Egypt
Age range
From 18 Years to 60 Years
Official registry ID
NCT06567587
Official title
Show the full official title

Assessing the Efficacy of Dexmedetomidine in Alleviating Agitation for Exacerbated COPD Patients Who Are Treated for Psychosis Requiring Non- Invasive Ventilation

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Tanta

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Tanta University, a university.

Did this study involve medication?

Yes. The study involved medication, including Dexmedetomidine.

Who was this study for?

Listed age limits: 18 years to 60 years.

Want to explore more studies?

Explore studies